Navigation Links
Girls with ovarian germ-cell tumors can safely skip chemotherapy unless disease recurs
Date:10/20/2010

BOSTON Researchers from Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) have found that as many as 50 percent of young girls treated for germ-cell ovarian tumors might safely be spared chemotherapy using a "watch and wait" strategy to determine if the follow-up treatment is needed.

In contrast to the current practice of administering chemotherapy to all patients following removal of these rare tumors, researchers said the study demonstrated that treatment could safely be delayed and given only if the cancer recurred.

Data from the trial involving 25 young women ages 9 to 16 are being presented at the 42nd Congress of the International Society of Paediatric Oncology (SIOP) in Boston on Friday, Oct. 22. The study was led by Lindsay Frazier, MD, a pediatric oncologist at DF/CHCC and chair of the Germ Cell Tumor Committee of the Children's Oncology Group.

"I personally think that not giving chemotherapy to half the patients [women with germ cell ovarian tumors] is a good thing," said Frazier. "The chemotherapy is just as effective given when the disease recurs. I would recommend that parents consider a watching and waiting strategy."

Germ cell tumors are malignancies that develop in precursors of sperm cells in boys and egg cells in girls. Some forms of the tumors are most often detected immediately following birth; other types are most common between the ages of 10 and 30.

Previous trials had shown that delaying chemotherapy was safe and effective in Stage 1 germ cell testicular tumors in boys. Over time, 30 percent of the patients developed a recurrence, but they were all cured by chemotherapy.

"So instead of giving 100 percent of them chemotherapy, only 30 percent needed it," explained Frazier, who said it's been found that the usual three cycles of chemotherapy administered for the tumors doubles the long-term risk of cardiovascular disease or second cancers.

The current study was undertaken to test a similar watch-and-wait approach in female patients. Frazier said 25 girls with Stage 1 germ cell ovarian tumors were recruited from about 100 medical centers an indication of the cancer's rarity. In all cases, the tumors had been completely removed by surgery.

Instead of undergoing chemotherapy immediately, the girls were monitored closely for signs of recurrence. Every three weeks their blood was tested for biochemical markers signifying a regrowth of the cancer, and every three months they were scanned with CT or MRI imaging.

"The median time to relapse was two months, and the latest relapse was at 9 months, so the families were not living with uncertainty for a long time," Frazier said.

The recurrence rate was 50 percent higher than in the boys with germ cell tumors but the delayed treatment was similarly effective though one girl died, yielding a survival rate of 96 percent.

Preventing unnecessary chemotherapy treatment for half of girls with such tumors is still desirable, said Frazier, "because there is evidence that girls are even more susceptible to long-term harm from chemo than boys are."


'/>"/>

Contact: Teresa Herbert
teresa_herbert@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Source:Eurekalert

Related medicine news :

1. Online Gambling Rises Among College Males, High School Girls
2. Girls with autism or ADHD symptoms not taken seriously
3. Absent Father Might Mean Earlier Puberty for Higher-Income Girls
4. Pediatric urologist performs innovative procedure for girls with rare vaginal defects
5. Many Girls Now Begin Puberty at Age 7, 8
6. SIDS surprise: Study finds that infant boys are more easily aroused from sleep than girls
7. New UN Entity Strengthens Global Efforts for Women & Girls
8. Exercise May Guard Girls Against Dementia in Senior Years
9. Teen Girls Becoming More Open to Drugs, Alcohol
10. UIC psychologist aims to reduce risky sexual behavior among African American girls
11. One-Third of U.S. Girls Get HPV Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Texas (PRWEB) , ... February 09, 2016 , ... ... reconstruction firm helping businesses recover after a disaster, announced today the acquisition of ... companies in Hawaii. , “Investing in like-minded companies who excel at ...
(Date:2/9/2016)... ... February 09, 2016 , ... Cirracore ... help enterprises move workloads to the cloud. Cirracore provides a secure VMware® ... without traversing the Internet. Transformation Solutions (TSL Partners) provides a full range ...
(Date:2/9/2016)... ... February 09, 2016 , ... On January 12, 2016 Paul ... appointment after they noticed their furnace not producing any heat. Shortly after entering the ... cracked heat exchanger was leaking dangerous levels of carbon monoxide into the home, at ...
(Date:2/9/2016)... California (PRWEB) , ... February 09, 2016 , ... ... of their new nationwide service to expand access to affordable hearing aids ... million hard of hearing individuals in the United States. , “For the average ...
(Date:2/9/2016)... ... February 09, 2016 , ... United ... In Praise of Prevention,” an animated video designed to prevent the ... translations of the video are being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... new report "Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015 - ... the North America continued to lead global ... translated into revenues worth US$ 16,907.3 million. ... Asia-Pacific , Latin America , ... anti-bacterial market is inclined towards North America ...
(Date:2/8/2016)... -- Respiratory Devices - Medical Devices Pipeline Assessment, ... report, " Respiratory Devices - Medical Devices Pipeline ... Devices currently in pipeline stage. The report ... comparative analysis of the products at various stages ... in the pipeline product development. It also provides ...
(Date:2/8/2016)... and FAIRFIELD, N.J. , Feb. 8, ... Pharmaceuticals, Inc. (Medimetriks) today announced that they have entered ... commercialization rights for OPA-15406 in the U.S. and ... manufacturing rights.  OPA-15406 is a topical, non-steroidal phosphodiesterase IV ... --> --> In ...
Breaking Medicine Technology: